Decoy Therapeutics Inc. (DCOY) stock
Close on Nov 11, 2026Market cap $714.15KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $714.15K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.56M
- EPS, diluted
- -$129.10
- Free cash flow
- -$5.40M
- Book value per share
- $5.38
- Diluted shares
- 1M
Trading
- Previous close
- $1.11
- Open
- $1.10
- Day's range
- $1.07 – $1.10
- Volume
- 16,373
- Average volume (20 days)
- 50,085
- Beta (5 years)
- 0.79
- 52-week range
- $0.90 – $20.76
- RSI (14 days)
- 36.9
- Volatility (1 year)
- 159.8%
- Relative volume
- 0.01×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DCOY | S&P 500 | Difference | DCOY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.9% | -2.4% | −23.4 pts | ||
| 3 months | -71.8% | -1.2% | −70.7 pts | ||
| Year to date | -86.0% | +12.3% | −98.3 pts | ||
| 1 year | -90.7% | +12.4% | −103.2 pts | ||
| 3 years | -99.9% | +78.8% | −178.7 pts | -90.1% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -86.8% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -78.9% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Decoy Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- News
About Decoy Therapeutics
Pharmaceutical Preparations
Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company dedicated to engineering and advancing a pipeline of novel peptide conjugate therapeutics. Using its proprietary IMP³ACT platform, the company combines artificial intelligence, machine learning, and rapid synthesis methods to create designable multi-antiviral candidates that target conserved mechanisms across enveloped viruses. Its primary development programs concentrate on infectious diseases and oncology, including a lead pan-coronavirus prophylactic nasal spray and a broad-spectrum respiratory antiviral covering influenza, respiratory syncytial virus, and coronavirus. The company designs its therapies for high-risk, immunocompromised patient populations and healthcare providers.
Company profile, executives and historyDecoy Therapeutics stock: common questions
What is Decoy Therapeutics's stock price?
DCOY closed at $1.09 on Nov 11, 2026, down 1.80% on the day. Over the past 52 weeks it traded between $0.90 and $20.76.
What is Decoy Therapeutics's market cap?
Decoy Therapeutics was worth $714.15K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DCOY's P/E ratio?
Decoy Therapeutics lost money over fiscal 2025 (diluted EPS -$129.10), so it has no meaningful P/E ratio.
Does Decoy Therapeutics pay a dividend?
No. Decoy Therapeutics has not paid a cash dividend over the last twelve months.
How has DCOY stock performed over the past year?
Including dividends, DCOY returned -90.7% over the past year, against +12.4% for the S&P 500.
How many DCOY shares are sold short?
0M shares were sold short at the latest FINRA report, 17.18% of the float, or 1.8 days of average trading volume.
Who are Decoy Therapeutics's competitors?
Companies most similar to Decoy Therapeutics by business, industry and size include COCP, INDP, ASMB, DNTH, DWTX.
See a number that looks wrong?